The table below shows Intellia Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$394.74M
-$348.88M
-$394.09M
-$333.29M
-$225.03M
-$49.91M
Capital expenditure
$1.13M
$5.78M
$13.98M
$13.56M
$12.76M
$3.58M
Investing cash flow
$228.03M
$125.57M
-$31.35M
$160.31M
-$550.78M
-$214.49M
Dividends paid
-
-
-
-
-
NTLA operating cash flow (10-K history)
Intellia Therapeutics, Inc. reported operating cash flow of -$394.74M for fiscal year 2025. That is down 13.1% from -$348.88M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $36.11M (FY 2016) to -$394.74M. Figures come from the company's audited annual reports as filed with the SEC.
